Johansson SG - Search Results

1

CD-sens: a biological measure of immunological changes stimulated by ASIT.

Nopp A, Cardell LO, Johansson SG, Oman H. Nopp A, et al. Among authors: johansson sg. Allergy. 2009 May;64(5):811-4. doi: 10.1111/j.1398-9995.2008.01900.x. Epub 2009 Feb 13. Allergy. 2009. PMID: 19220221

2

Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.

Nopp A, Johansson SG, Ankerst J, Bylin G, Cardell LO, Grönneberg R, Irander K, Palmqvist M, Oman H. Nopp A, et al. Among authors: johansson sg. Allergy. 2006 Mar;61(3):298-302. doi: 10.1111/j.1398-9995.2006.00987.x. Allergy. 2006. PMID: 16436137

3

The importance of IgE antibody levels in anti-IgE treatment.

Johansson SG, Oman H, Nopp A, Pettersson S. Johansson SG, et al. Allergy. 2006 Oct;61(10):1216-9. doi: 10.1111/j.1398-9995.2006.01172.x. Allergy. 2006. PMID: 16942572

4

Simultaneous exposure of several allergens has an additive effect on multisensitized basophils.

Nopp A, Johansson SG, Lundberg M, Oman H. Nopp A, et al. Among authors: johansson sg. Allergy. 2006 Nov;61(11):1366-8. doi: 10.1111/j.1398-9995.2006.01211.x. Allergy. 2006. PMID: 17002715

5

Cat IgA, representative of new carbohydrate cross-reactive allergens.

Adédoyin J, Grönlund H, Oman H, Johansson SG, van Hage M. Adédoyin J, et al. Among authors: johansson sg. J Allergy Clin Immunol. 2007 Mar;119(3):640-5. doi: 10.1016/j.jaci.2006.11.637. J Allergy Clin Immunol. 2007. PMID: 17336613

6

CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment.

Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H. Nopp A, et al. Among authors: johansson sg. Allergy. 2007 Oct;62(10):1175-81. doi: 10.1111/j.1398-9995.2007.01476.x. Allergy. 2007. PMID: 17845588 Clinical Trial.

7

Pholcodine caused anaphylaxis in Sweden 30 years ago.

Johansson SG, Oman H, Nopp A, Florvaag E. Johansson SG, et al. Allergy. 2009 May;64(5):820-1. doi: 10.1111/j.1398-9995.2009.01983.x. Allergy. 2009. PMID: 19210354 No abstract available.

8

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment.

Johansson SGO, Nopp A, Öman H, Ankerst J, Cardell LO, Grönneberg R, Matsols H, Rudblad S, Strand V, Stålenheim G. Johansson SGO, et al. Allergy. 2009 Oct;64(10):1472-1477. doi: 10.1111/j.1398-9995.2009.02051.x. Epub 2009 Apr 14. Allergy. 2009. PMID: 19393000 Clinical Trial.

9

After 6 years with Xolair; a 3-year withdrawal follow-up.

Nopp A, Johansson SG, Adédoyin J, Ankerst J, Palmqvist M, Oman H. Nopp A, et al. Among authors: johansson sg. Allergy. 2010 Jan;65(1):56-60. doi: 10.1111/j.1398-9995.2009.02144.x. Epub 2009 Oct 1. Allergy. 2010. PMID: 19796193

10

Anaphylaxis to Patent Blue V. II. A unique IgE-mediated reaction.

Johansson SG, Nopp A, Oman H, Stahl-Skov P, Hunting AS, Guttormsen AB. Johansson SG, et al. Allergy. 2010 Jan;65(1):124-9. doi: 10.1111/j.1398-9995.2009.02191.x. Epub 2009 Oct 5. Allergy. 2010. PMID: 19804438

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

344 results

Search Page